Halozyme Therapeutics (HALO) has faced a legal setback in Germany after a Higher Regional Court overturned a preliminary injunction that had previously blocked Merck (MRK) from distributing its Keytruda subcutaneous (SC) formulation in the country. The initial injunction, granted in December 2025, had prevented Merck from offering the drug in Germany. Halozyme expressed disappointment with the court's decision and plans to file a patent infringement lawsuit against Merck, seeking permanent relief.
The stock of Halozyme dropped by 2.9% following the announcement. Despite this setback, the company's shares have seen a significant rally this year, up 38.3% compared to the industry's 5.7% increase. The legal dispute revolves around Halozyme's MDASE patent portfolio, which covers technology for rapid subcutaneous drug administration.
In a separate but related development, a Dutch patent court ruled in Halozyme's favor in October 2026, prohibiting Merck from manufacturing, offering, selling, or using Keytruda SC in eight European countries. This ruling is independent of the German proceedings, meaning the German court's decision does not reverse the Dutch court's ruling.
Halozyme's MDASE patents are distinct from its ENHANZE drug delivery technology patents, ensuring that the outcome of the MDASE patent enforcement proceedings will not impact the company's ENHANZE licensing arrangements or related revenues. Halozyme has collaboration agreements with major pharmaceutical companies like Johnson & Johnson (JNJ) and argenx (ARGX), which use its ENHANZE technology for various drug formulations.